⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628485 | 0.79 | — | — | |
| SCHEMBL11921186 | 0.77 | — | — | |
| SCHEMBL18865137 | 0.75 | — | — | |
| SCHEMBL10039012 | 0.72 | — | — | |
| SCHEMBL17379087 | 0.71 | — | — | |
| SCHEMBL8141442 | 0.69 | — | — | |
| SCHEMBL2755085 | 0.65 | — | — | |
| SCHEMBL2628483 | 0.65 | — | — | |
| SCHEMBL6431138 | 0.64 | — | — | |
| SCHEMBL3250877 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718851-B2 | Deuterated nucleoside/tide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160130294-A1 | DEUTERATED NUCLEOSIDE/TIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150225386-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140275007-A1 | OXAMAZIN ANTIBIOTICS | SILICON VALLEY BANK | 2014-09-18 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633315-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130072483-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8163909-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7951838-B2 | Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110021515-A1 | DIHYROFUROPYRMINDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20100317668-A1 | SUBSTITUTED PYRANO [2,3-B] PYRIDINAMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7803809-B2 | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090036478-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-02-05 | — | — | US | disclosed |